Continuation of Suspension from Quotation
Filed with ASX · · 1 page · English
Summary by 6ix AI
Paradigm Biopharmaceuticals Limited has announced the continuation of the suspension of its securities from quotation on the ASX.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Appointment of Voluntary Administrators
- Board Initiates Voluntary Administration
- Continuation of Voluntary Suspension
- Agreement to Return US$2M to Obsidian
- Phase 3 Interim Result Below Continuation Threshold
Later from Paradigm Biopharmaceuticals
- PPS Shows Significant Pain Benefit in Rest of World Analysis
- Extension of Convening Period
- Convening Period Extended to 27 January 2027
- September 2026 Quarterly Activities Report & Appendix 4C
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals